CDKL5 and Dravet syndrome: However, a phase 2 clinical trial of non-aminoglycoside drug, Ataluren, was recently showed to be not effective for the treatment of nonsense mutations in CDKL5 deficiency disorder (CDD) and Dravet syndrome (DS) (Devinsky et al., 2021).